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Abstract: Marine natural products have been the focus of discovery for new products of 
chemical and pharmacological interest. The aim of this study was to evaluate the 
antinociceptive activity of the methanolic (ME), acetate (AE), hexanic (HE) and 
chloroform (CE) extracts obtained from Caulerpa mexicana, and ME, CE and HE obtained 
from Caulerpa sertularioides. These marine algae are found all over the world, mainly in 
tropical regions. Models such as the writhing test, the hot plate test and formalin-induced 
nociception test were used to evaluate antinociceptive activity in laboratory mice. In the 
writhing test, all the extracts were administered orally at a concentration of 100 mg/kg, and 
induced high peripheral antinociceptive activity, with a reduction in the nociception 
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induced by acetic acid above 65%. In the hot plate test, treatment with extracts from   
C. sertularioides (100 mg/kg, p.o.) did not significantly increase the latency of response, 
although the ME, AE and HE from C. mexicana showed activity in this model. This result 
suggests that these extracts exhibit antinociceptive activity. In the formalin test, it was 
observed that ME, AE and HE obtained from C. mexicana reduced the effects of formalin 
in both phases. On the other hand only CE from C. sertularioides induced significant 
inhibition of the nociceptive response in the first phase. To better assess the potential   
anti-inflammatory activity of the extracts, the carrageenan-induced peritonitis test was used 
to test Caulerpa spp. extracts on cell migration into the peritoneal cavity. In this assay, all 
extracts evaluated were able to significantly inhibit leukocyte migration into the peritoneal 
cavity in comparison with carrageenan. These data demonstrate that extracts from 
Caulerpa species elicit pronounced antinociceptive and anti-inflamatory activity against 
several nociception models. However, pharmacological and chemical studies are 
continuing in order to characterize the mechanism(s) responsible for the antinociceptive 
action and also to identify the active principles present in the Caulerpa species. 
Keywords: antinociceptive; anti-inflammatory; Caulerpa mexicana; Caulerpa sertularioide; 
marine algae 
 
1. Introduction 
The search for pharmacological properties from natural products has led to the discovery of 
pharmacologically active substances, with important applications both in the experimental field and 
identification of active principles with therapeutic interest [1–5]. Currently, about 25–30% of all active 
principles used in treatments are extracted from natural products [6]. The plant kingdom is responsible 
for the largest share of chemical diversity recorded in the literature to date and has contributed quite 
significantly to the research and discovery of new drugs of natural origin, as well as the supply of 
substances useful for treating diseases that affect living beings [7–11]. However, it should be noted 
that marine natural products have also been the focus of discovery of new products of chemical and 
pharmacological interest [12–18]. 
Nonetheless, only about 20% of natural products from around the world have had their extracts 
submitted to pharmacological or biological tests [19]. To make matters worse, extinction of many 
species has become more frequent, with an estimated thousand species becoming extinct each year on 
the planet. Many of these species have not yet even been described, cataloged or studied [20]. 
Marine organisms are sources of numerous new compounds with multiple pharmacological 
properties [21]. The variety and complexity of small molecules which are the secondary metabolites of 
plants and marine organisms is difficult to be obtained by chemical synthesis by laboratory methods, 
these being the direct result of millions of years of evolution, reaching highly refined forms for 
protection against the weather and resistance to climate, pollution and predators [22]. 
In general, algae synthesize secondary metabolites such as terpenoids [23], alkaloids [24], 
flavonoids [25], tannins [26] and acetogenins [27]. Polar polyphenols may also occur in high Mar. Drugs 2011, 9  
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concentrations [28,29]. In the literature, different pharmacological activities of macroalgae have been 
reported, including: antibacterial [30,31], antitumoral [32,33], anti-angiogenic [34,35], antiviral [36,37], 
antileishmania [38] and antioxidant [39] activity. However, in Brazil, this research field has not been 
well explored, despite the wealth of our marine flora. 
Recently, the hypothesis that Caulerpa species (Chlorophyta, order Caulerpales, family 
Caulerpaceae) produce secondary metabolites with possible antinociceptive actions was investigated. 
In our preliminary investigation of the crude methanolic extract and phases from another specie from 
algae, Caulerpa racemosa, our group showed that this specie also had antinociceptive activity in the 
same models described in this work [40]. Although marine algae are an important source for 
biologically active natural products, few studies, specifically in Brazil, have been conducted with the 
the purpose of evaluating antinociceptive and antiinflamatory activity in animal models. As such, this 
study intended to evaluate the antinociceptive activity of extracts of macroscopic green algae Caulerpa 
mexican and Caulerpa sertularioides in murine models. 
2. Results and Discussion 
The antinociceptive potential of extracts from algae of the genus Caulerpa was evaluated using 
three well-accepted murine pain models, namely acetic acid-induced writhing, hot plate and   
formalin-induced nociception tests. The acetic acid-induced abdominal writhing and hot plate test have 
been reported to be useful to investigate peripheral and central activity, respectively, while the 
formalin-induced nociception test is valuable in detecting both effects. 
Pre-treatment for all Caulerpa species resulted in significant inhibition of the acetic acid-induced 
writhing response. All extracts were evaluated at a dose of 100 mg/kg. The methanolic (ME), acetate 
(AE), hexanic (HE) and chloroform (CE) extracts from C. mexicana induced high peripheral 
antinociceptive activity with an inhibition of 78.4%, 73.2%, 83.1% and 77.0%, respectively. The 
pharmacological evaluation of extracts of C. sertularioides in the writhing test showed that the HE, 
CE, AE and ME induced inhibition of 66.5%, 67.0%, 60.7% and 67.0%, respectively. Moreover, these 
protective effects in the writhing test were also observed for dypirone (86.5%), as expected, used as 
the reference peripheral analgesic drug (Table 1). These data suggest that there is a possible 
antinociceptive action for extracts of C. Mexican and C. sertularioides. These data also corroborate a 
previous study on antinociceptive activity of Caulerpa racemosa [40]. 
The writhing test is commonly used for screening peripherally active analgesic. Algogenic agents, 
such as acetic acid, provoke a stereotypical behavior in mice characterized by abdominal contractions, 
movements of the body as a whole, twisting of dorso abdominal muscles and a reduction in motor 
activity and in motor coordination [41]. This model involves different nociceptive mechanisms, such 
as release of biogenic amines (e.g., histamine and serotonin), cyclooxygenases and their metabolites 
(e.g., PGE2 and PGF2α) [42] and opioid mechanisms [43]. Furthermore, it is well established that the 
nociceptive response caused by acetic acid is also dependent on the release of some cytokines, such as 
TNF-α, interleukin 1β and interleukin 8 via modulation of macrophages and mast cells localized in the 
peritoneal cavity [44]. In spite of compounds that act peripherally presenting action in this model, such 
as local anesthetics, muscle relaxants, ansiolitic, tranquilizers, among others, this remains being a good 
model to investigate the central analgesic action of substances. Because of this, the hot plate test was Mar. Drugs 2011, 9  
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carried out with the aim of evaluating whether the Caulerpa species could demonstrate an 
antinociceptive effect. 
Table 1. The antinociceptive effects of extracts from algae C. mexicana (100 mg/kg, p.o.), 
C. sertularioides (100 mg/kg, p.o.) and dipyrone (40 mg/kg, i.p.) in the acetic acid-induced 
writhing model in mice. 
  C. mexicana  C. sertularioides 
  Number of writhing 
Treatment  Mean ± S.E.M. 
a I  (%) 
b  Mean ± S.E.M. 
a I  (%) 
b 
Vehicle  35.5 ± 1.6  –  34.9 ± 1.9  – 
Dypirone  8.0 ± 2.3  86.5 **  5.9 ± 1.7  83.2 ** 
HE  6.0 ± 1.4  83.1 **  11.7 ± 2.0  66.5 ** 
CE  8.2 ± 2.3  77.0 **  11.5 ± 0.9  67.0 ** 
AE  9.5 ± 1.4  73.2 **  13.7 ± 2.8  60.7 ** 
ME  7.7 ± 0.7  78.4 **  11.5 ± 1.8  67.0 ** 
a Represents the Mean ± S.E.M. of 6 animals. Statistical differences between the treated and the 
control groups were evaluated by ANOVA and Dunnett tests and the asterisks denote the significance 
levels in comparison with control groups; ** P < 0.01; 
b Represents percentage inhibition.   
HE, hexanic; CE, chloroform; AE, acetate; ME, methanolic.  
Table 2. Time-course for response with treatment of C. mexicana extracts (100 mg/kg, p.o.) 
and morphine (4.3 mg/kg, s.c.) on thermal nociception (hot plate test). 
Animal Group 
Post-treatment (min) 
a
0 min  30 min  60 min  90 min  120 min  150 min 
Time latency (s) 
Control  1.4 ± 0.3  2.2 ± 0.6  1.8 ± 0.2  3.2 ± 0.3  2.8 ± 0.3  2.6 ± 0.5 
Morphine  6.9 ± 0.4  5.8 ± 0.3  12.8 ± 0.4 **  10.3 ± 0.8 **  9.7 ± 0.7 **  9.7 ± 0.9 **
ME  3.5 ± 0.5  3.0 ± 0.4  4.5 ± 0.3  5.4 ± 0.6 *  5.1 ± 0.8  5.4 ± 0.4 * 
AE  1.7 ± 0.4  3.4 ± 0.3  3.1 ± 0.5  5.3 ± 0.9 **  4.1 ± 0.5  5.9 ± 1.3 **
CE  2.7 ± 0.2  3.7 ± 0.5  4.4 ± 1.0  5.7 ± 0.7 *  3.6 ± 0.6  3.9 ± 1.0 
HE  2. 7 ± 0.3  2.8 ± 0.6  4.6 ± 0.7  5.8 ± 0.9 *  5.9 ± 1.0 *  5.1 ± 0.8 
a Results represents time latency in second (s). Represents the mean ± S.E.M. of 6 animals;   
* P < 0.05; ** P < 0.01 (ANOVA and Dunnett tests were used to evaluate the significance levels in 
comparison to time-zero). 
In the hot plate test, the extracts of C. sertularioides did not significantly increase the latency of 
response, indicating that they do not show central activity (data not shown). On the order hand, 
treatment with ME, AE, CE and HE from C. mexicana (Table 2) caused a marked increase in the 
latency time of the animals at the times of 90 and 150 (5.4 ± 0.6 s and 5.4 ± 0.4 s), 90 and 150  
(5.3 ± 0.9 s and 5.9 ± 1.3 s), 90 (5.7 ± 0.7 s) and 90–120 (5.8 ± 0.9 s; 5.9 ± 1.00 s) minutes 
respectively. These results suggest the action of analgesic activity for C. mexicana may be mediated 
through inhibition of pain receptors or inhibition of mediators like ciclooxigenase (i.e., COX-3). The 
treatment with morphine (4.3 mg/kg, s.c.), the opioid receptor agonist, induced a significant increase in 
latency time in the hot plate test, as expected, which persisted for at least 150 min. The hot plate test is Mar. Drugs 2011, 9  
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considered to be selective for centrally acting analgesic compounds, like morphine, while peripheral 
analgesics are known to be inactive on this kind of painful stimulus [45]. Although an effect in the hot 
plate test was observed, we cannot say that the effect of this extract is mediated centrally. 
Neurogenic and inflammatory pain were evaluated using the formalin test. The first phase 
corresponds to acute neurogenic pain, while the second phase corresponds to inflammatory pain. The 
first and second phases are generally believed to reflect excitation of peripheral afferent nociceptors 
and central sensitization, respectively [46,47]. Substance P and bradykinin participate in the first 
phase, while serotonin, histamine, bradykinin, nitric oxide and prostaglandins are involved in the 
second phase [48]. Different mechanisms have been shown to be involved in first and second phase 
nociceptive behaviors, based on the differential pharmacology associated with these behaviors. For 
example, while second phase behaviors are selectively attenuated by cyclooxygenase inhibitors, first 
and second phase behaviors are attenuated by opioids [47]. Treatment with HE, CE, AE and ME from 
C. mexicana induced an inhibition of 39.7%, 31.1%, 60.2% and 50.2%, respectively, in the first phase 
(Figure 1A). Furthemore, all extracts of C. mexicana induced significant inhibition in the second 
phase, with an inhibition of 47.7% (ME), 68.7% (AE) 45.8% (HE) and 37.9% (CE) (Figure 1B). The 
pharmacological evaluation of extracts of C. sertularioides in the formalin test showed that the CE and 
AE could reduce the duration (36.2% and 40.0% inhibition) of paw licking in the first phase 
(Figure 1C). On the other hand, in the second phase CE was not active, while ME, AE and HE, were 
able to decrease the time that animals spent licking the injected paw (55.8%, 64% and 47.5% 
inhibition, respectively) (Figure 1D). Treatment with indomethacin, the NSAID significantly inhibited 
formalin induced nociception in the second phase (48.7% inhibition), but not the first phase. Thus, the 
results shown in the first phase of the model corroborate with those obtained in the writhing test, 
confirming the antinociceptive activity of the extracts. 
Figure 1. Effect of extracts of algae C. mexicana, C. sertularioides and indomethacin 
administered orally at a dose of 100 mg/kg in the formalin test (6 animals). (A) and (C) 
represents 1st phase, (B) and (D) represents 2nd phase. Statistical differences between the 
treated and the control groups were evaluated using ANOVA and Dunnett tests and the 
asterisks denote the significance levels in comparison with control groups,   
* P < 0.05, ** P < 0.01. 
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Figure 1. Cont. 
  
Since reduction of the second phase in the formalin test implied a possible anti-inflammatory 
mechanism, and considering previous studies from our group [40] that have demonstrated that another 
specie of Caulerpa has anti-inflammatory activity, we decided to evaluate the activity of these species 
in models of cell migration. To determine the effects of extracts from Caulerpa spp. on peritoneal 
inflammation induced by carrageenan, the mice were treated with test samples. Using carrageenan as a 
stimulus, it was possible to produce an acute inflammatory response after 4 h in the peritoneal cavity of 
mice, with a large number of leukocytes in the exudates. With the aim of evaluating a possible inhibitory 
effect of Caulerpa spp. extracts on cell migration into the peritoneal cavity, the carrageenan-induced 
peritonitis test was used. In this assay, all extracts evaluated were able to significantly inhibit 
leukocyte migration into the peritoneal cavity in comparison with carrageenan. The HE, CE, AE and 
ME from C. mexicana inhibited 30.5%, 38.9%, 23.5%, 38.26%, respectively (Figure 2A). While the 
extracts from C. sertularioides induced inhibition of 61.8% (HE), 36.9%, (CE), 71.7% (AE) and   
49.25% (ME) (Figure 2B). The treatment with indomethacin inhibited 65.4% leukocyte migration.  
Figure 2. The effect of Caulerpa spp. extracts on cell migration. Caulerpa spp. extracts 
(100 mg/kg, p.o.) and indomethacin (35.7 mg/kg, p.o.) were evaluated using the 
carrageenan-induced peritoneal inflammation test. Each point represents the mean ± S.E.M. 
of six animals. Statistical differences between the treated and the control groups were 
evaluated by ANOVA and Dunnett tests, and the asterisks denote the significance levels in 
comparison with control groups, * P < 0.05, ** P < 0.01. 
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3. Experimental Section 
3.1. Extraction and Isolation 
The algae C. mexicana and C. sertularioide were collected from the coastal region of Bessa 
(7°03′52″S/34°49′51″W), João Pessoa, Paraíba State, Brazil in April 2008. The specimens were 
identified by Dr. George Emmanuel Cavalcanti de Miranda. Voucher specimens of C. mexicana  
(JPB 13985), C. sertularioides (JPB 13983) have been deposited in the Lauro Pires Xavier Herbarium 
at the Federal University of Paraíba (Universidade Federal da Paraíba), Brazil. The fresh algae were 
lyophilized and exhaustively extracted with hexane, chloroform, ethyl acetate, methanol and water in a 
Soxhlet apparatus, to obtain the respective extracts. 
3.2. Biological Activity Tests 
3.2.1. Drugs and Reagents 
The following drugs and reagents were used: acetic acid (Merck), dipyrone (Sigma Chemical), 
morphine sulfate (Dimorf-Cristalia-BR), indomethacin (Merck), arabic gum (Sigma Chemical) and 
Tween 20 (Sigma). A solution of formalin 2.5% was prepared with formaldehyde (Merck) in saline 
(NaCl 0.9%). The botanical material was used as suspensions in Tween 80 (s.q.f.) and arabic gum 
(vehicle) in all the experiments and were administered by oral route at a dose of 100 mg/kg. Dipyrone, 
morphine and indomethacin were used as reference drugs. Dipyrone and indomethacin were 
administered by oral route and morphine by subcutaneous route. The control group was composed of 
the vehicle (arabic gum). 
3.2.2. Animals 
All experiments were performed with male and female Swiss mice (20–25 g). Animals were 
maintained in a room at a controlled temperature of 22 ± 2 °C for 12-h light/dark cycle with free access 
to food and water. Eight hours before each experiment animals received only water, in order to avoid 
food interference with substance absorption. Animal care and research protocols were in accordance with 
the principles and guidelines for the care of laboratory animals and the ethical guidelines for 
investigations of experimental pain in conscious animals [49]. The experiments were performed with the 
approval of the protocol by the local Institutional Ethics Committee-UFAL (No. 006443/2005-78). 
3.2.3. Acetic Acid-Induced Writhing Test 
The writhing test was carried out as described by Koster et al. [50]. Groups of mice (n = 6) were 
treated with the methanolic (ME), ethyl acetate (AE), hexanic (HE) and chloroform (CE) extracts from 
Caulerpa species (100 mg/kg, p.o.), dipyrone (40 mg/kg, p.o.) and the vehicle (p.o.). The writhings 
were induced by intraperitoneal injection with a 0.6% acetic acid solution (0.1 mL/10 g) 40 min after 
treatment. The number of writhings were counted starting at 5 min after injection of the stimulus for 
20 min. Antinociceptive activity was expressed as percent inhibition of the usual number of writhings 
observed in control animals. Mar. Drugs 2011, 9  
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3.2.4. Hot Plate Test 
The hot plate test was performed following the method of Eddy and Leimbach [51]. Different 
groups of animals (n = 6) received ME, AE, HE and CE from Caulerpa species (100 mg/kg, p.o.), 
morphine (4.3 mg/kg, s.c.) and the vehicle (0.5 mL, p.o.) Then, mice were placed on the equipment, 
which was maintained at 55 ± 1 °C, and the reaction time was noted by observing either the licking of 
the fore and hind paws or jumping at 30, 60, 90, 120 and 150 min after administration of the extracts. 
The baseline was considered as the mean reaction time obtained at 30 min and 60 min before 
administration of the phases, compounds or morphine and was defined as the normal reaction of the 
animal to temperature. The cut-off time used to prevent skin damage was 15 s. 
3.2.5. Formalin-Induced Nociception 
The formalin test was carried out as described by Hunskaar, Hole and Tjølsen et al. [52,53]. 
Animals received a dose of 20 µL of a 2.5% formalin solution (0.92% formaldehyde, in saline) on the 
ventral surface of the right hind paw. Animals were observed from 0 to 5 min (neurogenic phase) and 
from 15 to 30 min (inflammatory phase) and the time that they spent licking the injected paw was 
recorded and considered as indicative of nociception. Animals received ME, AE, HE and CE from 
Caulerpa species (100 mg/kg, p.o.) or the standard drug (indomethacin, 35.7 mg/kg, p.o.) 40 min 
before formalin injection. Control animals received only the vehicle (arabic gum). 
3.2.6. Carrageenan-Induced Peritonitis in Mice 
For this series of experiments, the method described by Ferrándiz and Alcaraz [54] was used. 
Carrageenan (Sigma Aldrich) was freshly prepared (10 mg/mL) in sterile 0.9% w/v saline, and 250 μL 
was injected i.p. After 4 h, the animals were killed by cervical dislocation. The peritoneal cavity was 
washed with 1.5 mL cold PBS, and after gentle manual massage, the exudate was retrieved and its 
volume measured. The number of recruit leukocytes to the peritoneum was counted in a Neubauer 
chamber and results were expressed as cells × 10
6/mL. The exudate was collected and used freshly for 
cell counts and cytospin preparations. The Caulerpa extracts (100 mg/kg, p.o.), the carrageenan group 
(arabic gum, p.o.) and the reference drug (indomethacin, 35.7 mg/kg, p.o.) were administered 30 min 
before the carrageenan injection. In the negative control group, animals just received the same dose of 
a vehicle (arabic gum, p.o.) 30 min before the saline injection by intraperitoneal route. 
3.3. Statistical Analysis 
Data are reported as mean ± S.E.M. and were analyzed statistically using analysis of variance 
(ANOVA) followed by Dunnett’s test. Results with P < 0.05 were considered significant (* P < 0.05, 
** P < 0.01). 
4. Conclusions  
In conclusion, this study has shown that extracts from Caulerpa  species have significant 
antinociceptive and anti-inflammatory effects in laboratory animals at the dose and route investigated. Mar. Drugs 2011, 9  
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It can be argued that the extracts have antinociceptive activity and may possibly act via inhibition of 
inflammatory mediators. However, pharmacological and chemical studies are needed in order to 
characterize the mechanism(s) responsible for the antinociceptive and anti-inflammatory action and 
also to identify other active agents present in this plant. Moreover, the results obtained in this work 
contribute significantly to the pharmacological studies from marine products. 
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